Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

June 28, 2025

Study Completion Date

June 1, 2026

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

Fruquintinib Combined With Chemotherapy

"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1\. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."

Trial Locations (1)

Unknown

Zhejiang Cancer Institute & Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT05928312 - Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter